James McBrayer's guest appearances

James McBrayer

Centre for Independent Studies

The Bellcast

Chris Bennett

Peter Gray

Andrew Campion

James Holt

David Schwartz

Paul Thompson

Martin Barrett

Hamish Douglass

Andrew Weaver

Helen Chong

Alex Pollak

Rob Nash

Janus Henderson

Phil McKenzie

Simon Owen

OwlTail

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm's (ASX:CYC) MD &amp; CEO, James McBrayer.Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC's US journey gathers momentum with USFDA approval looming. The US is home to the world's largest nuclear medicine market. In this video James discusses: - (0:31) What CYC does &amp; its "imminent" entry into the US- (1:11) Key catalysts to drive share price growth- (1:47) Commercialising the product in the US- (2:46) CYC's product being endorsed to help fight COVID-19 in the US- (3:31) How the company has reduced its risks- (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm's (ASX:CYC) MD &amp; CEO, James McBrayer. Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC's US journey gathers momentum with USFDA approval looming. The US is home to the world's largest nuclear medicine market.  In this video James discusses:  - (0:31) What CYC does &amp; its "imminent" entry into the US - (1:11) Key catalysts to drive share price growth - (1:47) Commercialising the product in the US - (2:46) CYC's product being endorsed to help fight COVID-19 in the US - (3:31) How the company has reduced its risks - (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

From the helm: Cyclopharm's (ASX:CYC) MD & CEO, James McBrayer